Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples